Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim On-body Injector vs Pre-filled Syringe in Outpatient Chemotherapy for Malignant Lymphoma
jRCT1031260111Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pegfilgrastim in lymphosarcoma (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Incidence of febrile neutropenia. Started Apr 2026; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
lymphosarcoma
Beyond the preview
Go deeper on jRCT1031260111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260111.